AbbVie Inc.
AbbVie Expects Earnings Impact Due to Acquired IPR&D and Milestones Expense
Summary
AbbVie Inc. announced that it expects a $0.42 unfavorable impact on both GAAP and non-GAAP diluted earnings per share for the second quarter of 2025 due to acquired IPR&D and milestones expense of $823 million. The company's adjusted diluted earnings per share guidance for the full year 2025, including the impact of second quarter 2025 acquired IPR&D and milestones expense, is $11.67 - $11.87. This information is provided in Exhibit 99.1, which includes guidance for 2025 and the estimated acquired IPR&D and milestones expense incurred during the second quarter of 2025.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement